Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
26 05 2020
26 05 2020
Historique:
received:
17
03
2020
accepted:
02
04
2020
entrez:
27
5
2020
pubmed:
27
5
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
Methods for the development of clinical guidelines have advanced dramatically over the past 2 decades to strive for trustworthiness, transparency, user-friendliness, and rigor. The American Society of Hematology (ASH) guidelines on venous thromboembolism (VTE) have followed these advances, together with application of methodological innovations. In this article, we describe methods and methodological innovations as a model to inform future guideline enterprises by ASH and others to achieve guideline standards. Methodological innovations introduced in the development of the guidelines aim to address current challenges in guideline development. We followed ASH policy for guideline development, which is based on the Guideline International Network (GIN)-McMaster Guideline Development Checklist and current best practices. Central coordination, specialist working groups, and expert panels were established for the development of 10 VTE guidelines. Methodological guidance resources were developed to guide the process across guidelines panels. A methods advisory group guided the development and implementation of methodological innovations to address emerging challenges and needs. The complete set of VTE guidelines will include >250 recommendations. Methodological innovations include the use of health-outcome descriptors, online voting with guideline development software, modeling of pathways for diagnostic questions, application of expert evidence, and a template manuscript for publication of ASH guidelines. These methods advance guideline development standards and have already informed other ASH guideline projects. The development of the ASH VTE guidelines followed rigorous methods and introduced methodological innovations during guideline development, striving for the highest possible level of trustworthiness, transparency, user-friendliness, and rigor.
Sections du résumé
BACKGROUND
Methods for the development of clinical guidelines have advanced dramatically over the past 2 decades to strive for trustworthiness, transparency, user-friendliness, and rigor. The American Society of Hematology (ASH) guidelines on venous thromboembolism (VTE) have followed these advances, together with application of methodological innovations.
OBJECTIVE
In this article, we describe methods and methodological innovations as a model to inform future guideline enterprises by ASH and others to achieve guideline standards. Methodological innovations introduced in the development of the guidelines aim to address current challenges in guideline development.
METHODS
We followed ASH policy for guideline development, which is based on the Guideline International Network (GIN)-McMaster Guideline Development Checklist and current best practices. Central coordination, specialist working groups, and expert panels were established for the development of 10 VTE guidelines. Methodological guidance resources were developed to guide the process across guidelines panels. A methods advisory group guided the development and implementation of methodological innovations to address emerging challenges and needs.
RESULTS
The complete set of VTE guidelines will include >250 recommendations. Methodological innovations include the use of health-outcome descriptors, online voting with guideline development software, modeling of pathways for diagnostic questions, application of expert evidence, and a template manuscript for publication of ASH guidelines. These methods advance guideline development standards and have already informed other ASH guideline projects.
CONCLUSIONS
The development of the ASH VTE guidelines followed rigorous methods and introduced methodological innovations during guideline development, striving for the highest possible level of trustworthiness, transparency, user-friendliness, and rigor.
Identifiants
pubmed: 32453843
pii: S2473-9529(20)31310-0
doi: 10.1182/bloodadvances.2020001768
pmc: PMC7252554
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2351-2365Références
Blood Adv. 2018 Nov 27;2(22):3198-3225
pubmed: 30482763
Ann Intern Med. 2019 Aug 20;171(4):273-280
pubmed: 31330534
Med Decis Making. 2003 Mar-Apr;23(2):140-9
pubmed: 12693876
Med Care. 2004 Nov;42(11):1132-42
pubmed: 15586841
Ann Intern Med. 2015 Oct 6;163(7):548-53
pubmed: 26436619
Cochrane Database Syst Rev. 2017 Dec 29;12:CD006466
pubmed: 29285754
J Clin Epidemiol. 2013 Jul;66(7):726-35
pubmed: 23570745
PLoS Med. 2017 Jan 10;14(1):e1002207
pubmed: 28072838
Cochrane Database Syst Rev. 2018 Jun 19;6:CD006650
pubmed: 29920657
J Clin Epidemiol. 2015 May;68(5):597-600
pubmed: 25660962
BMJ. 2016 Jul 20;354:i3507
pubmed: 27443385
BMJ. 2016 Jun 28;353:i2016
pubmed: 27353417
J Clin Epidemiol. 2013 Jul;66(7):719-25
pubmed: 23312392
J Clin Epidemiol. 2011 Apr;64(4):401-6
pubmed: 21208779
J Clin Epidemiol. 2017 Jan;81:101-110
pubmed: 27713072
Blood Adv. 2018 Nov 27;2(22):3226-3256
pubmed: 30482764
J Clin Epidemiol. 2011 Apr;64(4):395-400
pubmed: 21194891
CMAJ. 2014 Feb 18;186(3):E123-42
pubmed: 24344144
Ann Intern Med. 2017 Jan 17;166(2):128-132
pubmed: 27893062
Blood Adv. 2019 Dec 10;3(23):3898-3944
pubmed: 31794602
Blood Adv. 2019 Dec 10;3(23):3867-3897
pubmed: 31794601
Ann Intern Med. 2020 Jan 7;172(1):46-56
pubmed: 31766052
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Blood Adv. 2018 Nov 27;2(22):3257-3291
pubmed: 30482765
CMAJ. 2010 Dec 14;182(18):E839-42
pubmed: 20603348
Blood Adv. 2018 Nov 27;2(22):3360-3392
pubmed: 30482768
Qual Life Res. 2006 Feb;15(1):1-14
pubmed: 16411026
Chest. 2004 Sep;126(3 Suppl):174S-178S
pubmed: 15383470
Blood Adv. 2020 Mar 10;4(5):953-968
pubmed: 32150612
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Cochrane Database Syst Rev. 2017 Sep 11;9:CD006652
pubmed: 28892556
Blood Adv. 2020 Jan 28;4(2):327-355
pubmed: 31985807
J Clin Epidemiol. 2016 Jan;69:225-34
pubmed: 26092286
Blood Adv. 2018 Nov 27;2(22):3292-3316
pubmed: 30482766
Ann Intern Med. 2012 Apr 3;156(7):525-31
pubmed: 22473437
Blood Adv. 2019 Dec 10;3(23):3945-3950
pubmed: 31794603
Respir Med. 2004 Dec;98(12):1195-202
pubmed: 15588040
Bull Am Coll Surg. 2012 Dec;97(12):39
pubmed: 23301322
Blood Adv. 2018 Nov 27;2(22):3317-3359
pubmed: 30482767
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
BMJ. 2016 Jun 30;353:i2089
pubmed: 27365494
J Clin Epidemiol. 2016 Dec;80:3-7
pubmed: 27452192
BMJ. 2019 Jul 19;366:l4606
pubmed: 31324659
Blood Adv. 2020 Jan 28;4(2):252
pubmed: 31945156
J Clin Epidemiol. 2011 Apr;64(4):383-94
pubmed: 21195583